Anacor Pharmaceuticals (NASDAQ:ANAC) traded with a cut of -0.08 points or -0.08% at $99.1 per share. As per the last available information, the stock aggregated $29.36 million in upticks and $27.06 million in downticks, keeping the net money flow capped at $2.3 million. The up/down ratio was found to be 1.08. For the week, the shares have seen a change of -0.21% in the share price.A block trade of $4.96 million in upticks and $3.93 million in downticks also took place during the day. The up/down ratio for the block stood at 1.26. The net money flow for this transaction was $1.02 million.
Currently the company Insiders own 4.5% of Anacor Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.26% . During last six month period, the net percent change held by insiders has seen a change of -7.29%. On the companys insider trading activities, The officer (Executive VP and CFO), of Anacor Pharmaceuticals, Inc., Bell Graeme had unloaded 751 shares at $99.28 per share in a transaction on June 1, 2016. The total value of transaction was $74,559. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Anacor Pharmaceuticals (NASDAQ:ANAC) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.07 points or 0.07% at $99.1 with 4,311,068 shares getting traded. Post opening the session at $99.14, the shares hit an intraday low of $99.08 and an intraday high of $99.3 and the price was in this range throughout the day. The company has a market cap of $4,496 million and the number of outstanding shares have been calculated to be 45,366,886 shares. The 52-week high of Anacor Pharmaceuticals (NASDAQ:ANAC) is $156.925 and the 52-week low is $52.
Many analysts have stated their opinion on the company shares. In a research note released to the investors, Mizuho Securities downgrades its rating on Anacor Pharmaceuticals (NASDAQ:ANAC).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on May 18, 2016.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Companys lead product candidate, AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Companys product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development, which include AN3365. The Companys compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).